1
|
Clergue-Duval V, Vrillon A, Jeanblanc J, Questel F, Azuar J, Fouquet G, Mouton-Liger F, Rollet D, Hispard E, Bouaziz-Amar E, Bloch V, Dereux A, Cognat E, Marie-Claire C, Laplanche JL, Bellivier F, Paquet C, Naassila M, Vorspan F. Plasma tau, NfL, GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot study. Addict Biol 2022; 27:e13232. [PMID: 36301211 DOI: 10.1111/adb.13232] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 08/24/2022] [Accepted: 08/26/2022] [Indexed: 01/24/2023]
Abstract
In this translational study, we investigated the plasma tau protein, neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), which are established biomarkers of neurological injury, as predictive biomarkers of alcohol withdrawal-associated brain toxicity. In the clinical study, patients with severe alcohol use disorder (AUD) on D1 of hospitalization for alcohol cessation (AC) (N = 36) were compared to severe AUD patients with at least 3 months of abstinence (N = 16). Overall, patients were 40 men (76.9%), aged 49.8 years [SD ±9.9]. Tau, NfL, GFAP and UCHL1 levels were measured using SIMOA and analysed with a quasipoisson regression model adjusted for age and sex. The NfL level was higher in the AC group (p = 0.013). In the AC group, the tau (p = 0.021) and UCHL1 (p = 0.021) levels were positively associated with the dose of diazepam per weight, and the tau (p = 0.045), NfL (p = 4.9 × 10-3 ) and UCHL1 (p = 0.036) levels were higher in the presence of signs of Wernicke's encephalopathy (n = 9). In the preclinical study, NfL and GFAP levels were assessed in the alcohol deprivation effect (ADE) procedure (N = 17) and control Wistar rats (N = 15). Furthermore, ADE rats were prospectively assessed: after 24 h (T1) and 3 weeks of AC (T2) (paired-samples Wilcoxon and Mann-Whitney tests). The NfL level was higher in the ADE model than in the control rats at both T1 and T2 (p = 0.033 and p = 1.3 × 10-3 ) and higher at T2 than at T1 (p = 0.040). Plasma tau, NfL and UCHL1 are potential biomarkers of brain suffering during alcohol withdrawal.
Collapse
Affiliation(s)
- Virgile Clergue-Duval
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Agathe Vrillon
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Jérôme Jeanblanc
- Inserm UMRS-1247 Groupe de recherche sur l'alcool et les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.,FHU Améliorer le pronostic des troubles Addictifs et Mentaux par une Médecine Personnalisée (A2M2P), Amiens, France
| | - Frank Questel
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Julien Azuar
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Grégory Fouquet
- Inserm UMRS-1247 Groupe de recherche sur l'alcool et les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.,FHU Améliorer le pronostic des troubles Addictifs et Mentaux par une Médecine Personnalisée (A2M2P), Amiens, France
| | - François Mouton-Liger
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Dorian Rollet
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Eric Hispard
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Elodie Bouaziz-Amar
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Département de Biochimie et Biologie Moléculaire, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,UFR de Pharmacie, Université Paris Cité, Paris, France
| | - Vanessa Bloch
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Pharmacie, Université Paris Cité, Paris, France.,Service de Pharmacie, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Alexandra Dereux
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Resalcog (Réseau pour la prise en charge des troubles cognitifs liés à l'alcool), Paris, France
| | - Emmanuel Cognat
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Cynthia Marie-Claire
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France
| | - Jean-Louis Laplanche
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,Département de Biochimie et Biologie Moléculaire, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,UFR de Pharmacie, Université Paris Cité, Paris, France
| | - Frank Bellivier
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France
| | - Claire Paquet
- Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France.,Centre de Neurologie Cognitive, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Mickael Naassila
- Inserm UMRS-1247 Groupe de recherche sur l'alcool et les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.,FHU Améliorer le pronostic des troubles Addictifs et Mentaux par une Médecine Personnalisée (A2M2P), Amiens, France.,UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France
| | - Florence Vorspan
- Département de Psychiatrie et de Médecine Addictologique, APHP GHU Nord, Site Lariboisière Fernand-Widal, Paris, France.,Inserm UMRS-1144 Optimisation thérapeutique en neuropsychopharmacologie, Université Paris Cité, Paris, France.,FHU Network of Research in Substance Use Disorders (NOR-SUD), Paris, France.,UFR de Médecine, Université Paris Cité, Paris, France
| |
Collapse
|
2
|
Deschamps C, Uyttersprot F, Debris M, Marié C, Fouquet G, Marcq I, Vilpoux C, Naassila M, Pierrefiche O. Anti-inflammatory drugs prevent memory and hippocampal plasticity deficits following initial binge-like alcohol exposure in adolescent male rats. Psychopharmacology (Berl) 2022; 239:2245-2262. [PMID: 35314896 DOI: 10.1007/s00213-022-06112-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 03/01/2022] [Indexed: 11/30/2022]
Abstract
RATIONALE Binge drinking during adolescence impairs learning and memory on the long term, and many studies suggest a role of neuroinflammation. However, whether neuroinflammation occurs after the very first exposures to alcohol remains unclear, while initial alcohol exposure impairs learning for several days in male rats. OBJECTIVES To investigate the role of neuroinflammation in the effects of only two binge-like episodes on learning and on neuronal plasticity in adolescent male rat hippocampus. METHODS Animals received two ethanol i.p. injections (3 g/kg) 9 h apart. Forty-eight hours later, we recorded long-term depression (LTD) and potentiation (LTP) in CA1 area of hippocampus slices. In isolated CA1, we measured immunolabelings for microglial activation and Toll-like receptor 4 (TLR4) and mRNA levels for several cytokines. RESULTS Forty-eight hours after the two binges, rats performed worse than control rats in novel object recognition, LTD was reduced, LTP was increased, and excitatory neurotransmission was more sensitive to an antagonist of the GluN2B subunit of the NMDA receptor. Exposure to ethanol with minocycline or indomethacin, two anti-inflammatory drugs, or with a TLR4 antagonist, prevented all effects of ethanol. Immunolabelings at 48 h showed a reduction of neuronal TLR4 that was prevented by minocycline pretreatment, while microglial reactivity was undetected and inflammatory cytokines mRNA levels were unchanged. CONCLUSION Two binge-like ethanol exposures during adolescence in rat involved neuroinflammation leading to changes in TLR4 expression and in GluN2B functioning inducing disturbances in synaptic plasticity and cognitive deficits. Anti-inflammatory drugs are good candidates to prevent brain function and memory deficits induced by few binge-drinking episodes.
Collapse
Affiliation(s)
- Chloé Deschamps
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Floriane Uyttersprot
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Margot Debris
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Constance Marié
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Grégory Fouquet
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Ingrid Marcq
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Catherine Vilpoux
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Mickael Naassila
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France
| | - Olivier Pierrefiche
- UMR1247 INSERM, Groupe de Recherche Sur L'Alcool Et Les Pharmacodépendances, Université de Picardie Jules Verne, Centre Universitaire de Recherche en Santé, Chemin du Thil, 80025, Amiens, France.
| |
Collapse
|
3
|
Legendre P, Chapuis N, Régent A, Ribeiro E, Fouquet G, Deau-Fischer B, Retornaz F, Terrier B. Spectre des maladies auto-immunes ou inflammatoires associées à une prolifération T clonale de signification indéterminée. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
4
|
Meinhardt MW, Pfarr S, Fouquet G, Rohleder C, Meinhardt ML, Barroso-Flores J, Hoffmann R, Jeanblanc J, Paul E, Wagner K, Hansson AC, Köhr G, Meier N, von Bohlen und Halbach O, Bell RL, Endepols H, Neumaier B, Schönig K, Bartsch D, Naassila M, Spanagel R, Sommer WH. Psilocybin targets a common molecular mechanism for cognitive impairment and increased craving in alcoholism. Sci Adv 2021; 7:eabh2399. [PMID: 34788104 PMCID: PMC8598005 DOI: 10.1126/sciadv.abh2399] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 09/28/2021] [Indexed: 05/21/2023]
Abstract
Alcohol-dependent patients commonly show impairments in executive functions that facilitate craving and can lead to relapse. However, the molecular mechanisms leading to executive dysfunction in alcoholism are poorly understood, and new effective pharmacological treatments are desired. Here, using a bidirectional neuromodulation approach, we demonstrate a causal link between reduced prefrontal mGluR2 function and both impaired executive control and alcohol craving. A neuron-specific prefrontal mGluR2 knockdown in rats generated a phenotype of reduced cognitive flexibility and excessive alcohol seeking. Conversely, virally restoring prefrontal mGluR2 levels in alcohol-dependent rats rescued these pathological behaviors. In the search for a pharmacological intervention with high translational potential, psilocybin was capable of restoring mGluR2 expression and reducing relapse behavior. Last, we propose a FDG-PET biomarker strategy to identify mGluR2 treatment-responsive individuals. In conclusion, we identified a common molecular pathological mechanism for both executive dysfunction and alcohol craving and provided a personalized mGluR2 mechanism-based intervention strategy for medication development for alcoholism.
Collapse
Affiliation(s)
- Marcus W. Meinhardt
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
- Corresponding author. (M.W.M.); (W.H.S.); (R.S.)
| | - Simone Pfarr
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Grégory Fouquet
- Université de Picardie Jules Verne, INSERM UMRS, 1247 Amiens, France
| | - Cathrin Rohleder
- Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Department of Multimodal Imaging, Max Planck Institute for Neurological Research, Cologne, Germany
- Brain and Mind Centre, The University of Sydney, Sydney, Australia
| | - Manuela L. Meinhardt
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Janet Barroso-Flores
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Rebecca Hoffmann
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Jérôme Jeanblanc
- Université de Picardie Jules Verne, INSERM UMRS, 1247 Amiens, France
| | - Elisabeth Paul
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Konstantin Wagner
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Anita C. Hansson
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
| | - Georg Köhr
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
- Department of Neurophysiology, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Nils Meier
- Institute for Anatomy and Cell Biology, Universitätsmedizin Greifswald, Greifswald, Germany
| | | | - Richard L. Bell
- Department of Psychiatry, Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Heike Endepols
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Department of Multimodal Imaging, Max Planck Institute for Neurological Research, Cologne, Germany
- Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine, Nuclear Chemistry (INM-5), Jülich, Germany
| | - Bernd Neumaier
- Institute of Radiochemistry and Experimental Molecular Imaging, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- Institute for Anatomy and Cell Biology, Universitätsmedizin Greifswald, Greifswald, Germany
| | - Kai Schönig
- Department of Molecular Biology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Dusan Bartsch
- Department of Molecular Biology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
| | - Mickaël Naassila
- Université de Picardie Jules Verne, INSERM UMRS, 1247 Amiens, France
| | - Rainer Spanagel
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
- Corresponding author. (M.W.M.); (W.H.S.); (R.S.)
| | - Wolfgang H. Sommer
- Institute of Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, 68159 Mannheim, Germany
- Department of Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
- Corresponding author. (M.W.M.); (W.H.S.); (R.S.)
| |
Collapse
|
5
|
Fouquet G, Wartski M, Dechmi A, Willems L, Deau‐Fischer B, Franchi P, Descroocq J, Deschamps P, Clerc J, Bouscary D, Barreau S, Chapuis N, Vignon M, Cottereau A. PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPY. Hematol Oncol 2021. [DOI: 10.1002/hon.99_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- G. Fouquet
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - M. Wartski
- Cochin Hospital APHP, Paris Nuclear Medicine Paris France
| | - A. Dechmi
- Cochin Hospital APHP, Paris Nuclear Medicine Paris France
| | - L. Willems
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | | | - P. Franchi
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - J. Descroocq
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - P. Deschamps
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - J. Clerc
- Cochin Hospital APHP, Paris Nuclear Medicine Paris France
| | - D. Bouscary
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | - S. Barreau
- Hôpital Cochin APHP Service d'hématologie biologique Paris France
| | - N. Chapuis
- Hôpital Cochin APHP Service d'hématologie biologique Paris France
| | - M. Vignon
- Cochin Hospital APHP, Paris, France Hematology Paris France
| | | |
Collapse
|
6
|
Lacout C, Fouquet G, Terriou L, Millot G, Lavigne C, Orvain C, Dhôte R, Hamel J, Bloch-Queyrat C, Hermine O, Urbanski G. Risque infectieux de l’étoposide dans l’hémophagocytose lymphohistiocytaire de l’adulte. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Urbanski G, Terriou L, Fouquet G, Hamel J, Lavigne C, Orvain C, Larroche C, Hermine O, Bloch-Queyrat C, Lacout C. Facteurs associés à la mortalité à J30 dans l’hémophagocytose lymphohistiocytaire chez l’adulte : construction d’un score de mortalité à partir d’une cohorte multicentrique de 170 patients et validation sur une cohorte de 118 patients. Rev Med Interne 2020. [DOI: 10.1016/j.revmed.2020.10.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Drissi I, Deschamps C, Fouquet G, Alary R, Peineau S, Gosset P, Sueur H, Marcq I, Debuysscher V, Naassila M, Vilpoux C, Pierrefiche O. Memory and plasticity impairment after binge drinking in adolescent rat hippocampus: GluN2A/GluN2B NMDA receptor subunits imbalance through HDAC2. Addict Biol 2020; 25:e12760. [PMID: 31056842 DOI: 10.1111/adb.12760] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Revised: 03/18/2019] [Accepted: 03/19/2019] [Indexed: 12/11/2022]
Abstract
Ethanol (EtOH) induces cognitive impairment through modulation of synaptic plasticity notably in the hippocampus. The cellular mechanism(s) of these EtOH effects may range from synaptic signaling modulation to alterations of the epigenome. Previously, we reported that two binge-like exposures to EtOH (3 g/kg, ip, 9 h apart) in adolescent rats abolished long-term synaptic depression (LTD) in hippocampus slices, induced learning deficits, and increased N-methyl-d-aspartate (NMDA) receptor signaling through its GluN2B subunit after 48 hours. Here, we tested the hypothesis of EtOH-induced epigenetic alterations leading to modulation of GluN2B and GluN2A NMDA receptor subunits. Forty-two days old rats were treated with EtOH or the histone deacetylase inhibitor (HDACi) sodium butyrate (NaB, 600 mg/kg, ip) injected alone or 30 minutes before EtOH. After 48 hours, learning was tested with novel object recognition while synaptic plasticity and the role of GluN2A and GluN2B subunits in NMDA-fEPSP were measured in CA1 field of hippocampus slices. LTD and memory were impaired 48 hours after EtOH and NMDA-fEPSP analysis unraveled changes in the GluN2A/GluN2B balance. These results were associated with an increase in histone deacetylase (HDAC) activity and HDAC2 mRNA and protein while Ac-H4K12 labelling was decreased. EtOH increases expression of HDAC2 and mRNA level for GluN2B subunit (but not GluN2A), while HDAC2 modulates the promoter of the gene encoding GluN2B. Interestingly, NaB pretreatment prevented all the cellular and memory-impairing effects of EtOH. In conclusion, the memory-impairing effects of two binge-like EtOH exposure involve NMDA receptor-dependent LTD deficits due to a GluN2A/GluN2B imbalance resulting from changes in GluN2B expression induced by HDAC2.
Collapse
Affiliation(s)
- Ichrak Drissi
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Chloé Deschamps
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Grégory Fouquet
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Rachel Alary
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Stéphane Peineau
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Philippe Gosset
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Harold Sueur
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Ingrid Marcq
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Véronique Debuysscher
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Mickael Naassila
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Catherine Vilpoux
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| | - Olivier Pierrefiche
- UPJV, INSERM UMR 1247 GRAP, Groupe de Recherche sur l'Alcool et les Pharmacodépendances, Centre Universitaire de Recherche en Santé (CURS) Amiens Cedex 1 France
| |
Collapse
|
9
|
Vanlaeys A, Fouquet G, Kischel P, Hague F, Pasco-Brassart S, Lefebvre T, Rybarczyk P, Dhennin-Duthille I, Brassart B, Ouadid-Ahidouch H, Gautier M. Cadmium exposure enhances cell migration and invasion through modulated TRPM7 channel expression. Arch Toxicol 2020; 94:735-747. [PMID: 32080757 DOI: 10.1007/s00204-020-02674-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2019] [Accepted: 02/11/2020] [Indexed: 12/26/2022]
Abstract
Cadmium is a xenobiotic involved in neoplastic transformation. Cadmium enters the cells through divalent cation transporters including the Transient Receptor Potential Melastatin-related 7 (TRPM7) which is known to be involved in cancer cell fate. This work aimed to study the role of TRPM7 in neoplastic transformation induced by cadmium exposure in non-cancer epithelial cells. Non-cancer epithelial cells were chronically exposed to low-dose of cadmium. TRPM7 expression and function were studied by Western-Blot, Patch-Clamp and calcium and magnesium imaging. Finally, cell migration and invasion were studied by Boyden chamber assays. Chronic cadmium exposure induced TRPM7 overexpression and increased the membrane currents (P < 0.001). Cells exposed to cadmium had higher intracellular calcium and magnesium levels (P < 0.05). TRPM7 silencing restored calcium levels but strongly decreased intracellular magnesium concentration (P < 0.001). Moreover, cadmium exposure enhanced both cell migration and invasion, but TRPM7 silencing strongly decreased these features (P < 0.001). Furthermore, mammary epithelial cells exposed to cadmium became rounded and had less cell-to-cell junctions. Cadmium exposure decreased epithelial markers while the mesenchymal ones were increased. Importantly, TRPM7 silencing was able to reverse these phenotypic modifications (P < 0.05). To summarize, our data show that chronic cadmium exposure enhanced TRPM7 expression and activity in non-cancer epithelial cells. TRPM7 overexpression induced intracellular magnesium increase and stimulated cell migration and invasion. These neoplastic properties could be linked to a TRPM7-dependent epithelial-to-mesenchymal transition reprogramming in cell exposed to cadmium. These findings provide new insights into the regulation of cell fates by cadmium exposure.
Collapse
Affiliation(s)
- Alison Vanlaeys
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Grégory Fouquet
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Philippe Kischel
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Frédéric Hague
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Sylvie Pasco-Brassart
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Université de Reims Champagne Ardenne (URCA), 51095, Amiens, France
| | - Thibaut Lefebvre
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Pierre Rybarczyk
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
- Anatomie et Cytologie Pathologiques, CHU Amiens-Picardie, Amiens, France
| | - Isabelle Dhennin-Duthille
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Bertrand Brassart
- UMR CNRS 7369 Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), Université de Reims Champagne Ardenne (URCA), 51095, Amiens, France
| | - Halima Ouadid-Ahidouch
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France
| | - Mathieu Gautier
- Laboratoire de Physiologie Cellulaire et Moléculaire - UR UPJV 4667, UFR Sciences, Université de Picardie Jules Verne (UPJV), 80039, Amiens, France.
| |
Collapse
|
10
|
Youssoufa A, Decormeille G, Michel P, Jacq G, Brouard F, Aissaoui N, Barbar S, Belaizi N, Boissier F, Boulinguiez C, Chauvin V, Corrolleur C, Dame S, Da Silva D, Dauvergne J, Domitien J, Fouquet G, Garin C, Gay P, Grimaldi D, Hamzaoui O, Joosten A, Kimoune A, Lacherade JC, Lascarroux JB, Legrain L, Macciotta Y, Mengus A, Ory S, Papin S, Payen S, Pereira F, Piton G, Rodriguez S, Rodriguez T, Simon M, Laurent-Taluy L, Toure E, Turia S, Villette E, Bejaud S, Merand F, Muller G, Hraiech S. Impact du nombre d’interventions infirmières sur la durée d’administration des catécholamines chez les patients de réanimation : étude INTERVAL. Méd Intensive Réa 2018. [DOI: 10.3166/rea-2018-0044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Objectifs : Bien que quotidiennement géré par les infirmier(ière)s diplômé(e)s d’État (IDE) de réanimation, le sevrage des catécholamines a rarement été étudié. L’hypothèse de notre étude était que l’augmentation du nombre d’interventions menées sur la vitesse de perfusion des catécholamines permettait de raccourcir la durée d’administration de celles-ci.
Patients et méthodes : Il s’agissait d’une étude prospective observationnelle dans 21 réanimations. Tous les patients traités par vasopresseurs pendant la période d’étude ont été inclus. Le nombre d’interventions effectuées par l’IDE en charge du patient sur la vitesse d’administration des catécholamines était noté toutes les quatre heures. La posologie de catécholamines en cours ainsi que la pression artérielle moyenne (PAM) du patient étaient également relevées. Les facteurs influençant la rapidité du sevrage des catécholamines étaient également analysés.
Résultats : Nous avons inclus 226 patients dont l’âge moyen était de 65 ± 14 ans. La durée moyenne du traitement par catécholamines était de 71,6 (±81) heures. Le nombre d’interventions IDE par quatre heures était de 1,9 (±2,8) intervention. La durée du traitement par catécholamines était significativement moindre lorsque le nombre d’interventions augmentait (p = 0,04). L’existence d’un protocole spécifique à la gestion des catécholamines raccourcissait leur durée de sevrage. Un IGS2 élevé, une PAM élevée ainsi que la période diurne étaient associés à une augmentation du nombre des interventions IDE.
Conclusion : Le nombre d’interventions par les IDEs menées sur la perfusion de catécholamines était inversement lié à la durée du traitement par catécholamines. Des études complémentaires permettront d’évaluer l’impact de ces interventions sur le pronostic des patients.
Collapse
|
11
|
Fouquet G, Debuysscher V, Ouled-Haddou H, Eugenio MS, Demey B, Singh AR, Ossart C, Al Bagami M, Regimbeau JM, Nguyen-Khac E, Naassila M, Marcq I, Bouhlal H. Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. Oncotarget 2018; 7:32493-503. [PMID: 27081035 PMCID: PMC5078028 DOI: 10.18632/oncotarget.8679] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Accepted: 03/28/2016] [Indexed: 12/30/2022] Open
Abstract
Multidrug resistance MDR proteins (MRPs) are members of the C family of a group of proteins named ATP binding cassette (ABC) transporters. MRPs can transport drugs including anticancer drugs, nucleoside analogs, antimetabolites and tyrosine kinase inhibitors. Drugs used in HCC therapy, such as tyrosine kinase inhibitor sorafenib, are substrates of uptake and/or efflux transporters. Variable expression of MRPs at the plasma membrane of tumor cells may contribute to drug resistance and subsequent clinical response. Recently, we reported that the hepatocyte SLAMF3 expression (Signaling Lymphocytic Activation Molecule Family member 3) was reduced in tumor cells from hepatocellular carcinoma (HCC) compared to its high expression in adjacent tissues. In the present study, we make a strong correlation between induced SLAMF3 overexpression and the specific loss of MRP-1 expression and its functionalities as a drugs resistance transporter. No changes were observed on expression of ABCG2 and MDR. More importantly, we highlight a strong inverse correlation between MRP-1 and SLAMF3 expression in patients with HCC. We propose that the SLAMF3 overexpression in cancerous cells could represent a potential therapeutic strategy to improve the drugs sensibility of resistant cells and thus control the therapeutic failure in HCC patients.
Collapse
Affiliation(s)
- Grégory Fouquet
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Véronique Debuysscher
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Hakim Ouled-Haddou
- EA 4666 LNPC, Centre Universitaire de Recherche en Santé CURS, CAP-Santé (FED 4231) Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Mélanie Simoes Eugenio
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Baptiste Demey
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Amrathlal Rabbind Singh
- Department of Microbiology, Dr. G. Venkataswamy Eye Research Institute, Aravind Medical Research Foundation, Madurai, India
| | - Christèle Ossart
- Service de Thérapie Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Mohammed Al Bagami
- EA 4666 LNPC, Centre Universitaire de Recherche en Santé CURS, CAP-Santé (FED 4231) Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Jean-Marc Regimbeau
- Service de Chirurgie Digestive Centre Hospitalier Universitaire Sud, Amiens, France
| | - Eric Nguyen-Khac
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France.,Service Hépato-Gastroenterologie, Centre Hospitalier Universitaire Sud, Amiens, France
| | - Mickael Naassila
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Ingrid Marcq
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| | - Hicham Bouhlal
- INSERM-ERi 24 (GRAP) Centre Universitaire de Recherche en Santé CURS, Université de Picardie Jules Verne, Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France.,Service de Thérapie Cellulaire Centre Hospitalier Universitaire Sud, Amiens, France
| |
Collapse
|
12
|
Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. Ann Oncol 2016; 27:902-7. [PMID: 26787238 DOI: 10.1093/annonc/mdw017] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Accepted: 01/07/2016] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND The IFM2009-02 trial studied pomalidomide (4 mg daily, 21/28 versus 28/28) and dexamethasone in very advanced relapsed or refractory multiple myeloma (RRMM). We observed that 40% of patients had a prolonged progression-free survival (PFS) and subsequently overall survival (OS). We sought to analyze the characteristics of these patients and study the effect of long exposure to pomalidomide. DESIGN We separated the studied population into two groups: 3 months to 1 year (<1 year) and more than 1 year (≥1 year) of treatment with pomalidomide and dexamethasone based on clinical judgment and historical control studies. We then analyzed the characteristics of patients according to duration of treatment. RESULTS The overall response rate (ORR) for the <1-year group was 43%, the median PFS 4.6 months [95% confidence interval (95% CI) 3.8-6.4] with only 6% at 12 months, and the median OS was 15 months (11.7-20.3) and 40% at 18 months. For the ≥1-year group, the response rate and survival were strikingly different, ORR at 83%, median PFS 20.7 months (14.7-35.4), median OS not reached, and 91% at 18 months. CONCLUSION Pomalidomide and dexamethasone favored prolonged and safe exposure to treatment in 40% of heavily treated and end-stage RRMM, a paradigm shift in the natural history of RRMM characterized with a succession of shorter disease-free intervals and ultimately shorter survival. Although an optimization of pomalidomide-dexamethasone regimen is warranted in advanced RRMM, we claim that pomalidomide has proven once more to change the natural history of myeloma in this series, which should be confirmed in a larger study.
Collapse
Affiliation(s)
- G Fouquet
- Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille
| | - B Pegourie
- Department of Hematology, Hôpital A.Michallon, CHU Grenoble, Grenoble
| | - M Macro
- Department of Hematology, Hôpital Côte de Nacre, CHU Caen, Caen
| | - M O Petillon
- Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille
| | - L Karlin
- Department of Hematology, Centre Hospitalier Lyon-Sud, Lyon
| | - D Caillot
- Department of Hematology, CHU de Dijon, Dijon
| | - M Roussel
- Department of Hematology, CHU de Toulouse, Toulouse
| | - B Arnulf
- Department of Hematology, Hôpital Saint Louis, APHP, Paris
| | - C Mathiot
- Intergroupe Francophone du Myélome (IFM)
| | - G Marit
- Department of Hematology and Cell Therapy Service, CHU de Bordeaux, Pessac, France
| | - B Kolb
- Department of Hematology, Hôpital Robert Debré, CHU Reims, Reims
| | - A M Stoppa
- Department of Hematology, Institut Paoli Calmettes, Marseille
| | - S Brechiniac
- Department of Hematology, CHU Avicennes, APHP, Paris
| | - V Richez
- Department of Hematology, CHU Nice, Nice
| | - P Rodon
- Department of Hematology, CH de Périgueux, Périgueux
| | - A Banos
- Department of Hematology, CH de la Côte Basque, Bayonne
| | - M Wetterwald
- Department of Hematology, CH de Dunkerque, Dunkerque
| | - L Garderet
- Department of Hematology, CHU St-Antoine, Paris
| | - B Royer
- Department of Hematology, Hôpital Sud, CHU Amiens, Amiens
| | - C Hulin
- Department of Hematology, Hôpital de Nancy, Nancy
| | - L Benbouker
- Department of Hematology, Hôpital de Tours, Tours
| | - O Decaux
- Department of Hematology, CHU Rennes, Rennes
| | | | - J P Fermand
- Department of Hematology, Hôpital Saint Louis, APHP, Paris
| | - M Attal
- Department of Hematology, CHU de Toulouse, Toulouse
| | | | - P Moreau
- Department of Hematology, CHU Nantes, Nantes
| | - T Facon
- Department of Blood Diseases, Hôpital Huriez, CHRU Lille, Lille
| | - X Leleu
- Department of Hematology, CHU Poitiers, Poitiers
| | | |
Collapse
|
13
|
Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, Le Grand C, Prodhomme C, Renaud L, Bories C, Herbaux C, Karlin L, Roussel M, Benboubker L, Hulin C, Arnulf B, Leleu X. [Pomalidomide for multiple myeloma]. Rev Med Interne 2015; 36:613-8. [PMID: 26257103 DOI: 10.1016/j.revmed.2015.04.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 03/08/2015] [Accepted: 04/22/2015] [Indexed: 11/30/2022]
Abstract
Once characterized by a very poor outcome, multiple myeloma (MM) now has a significantly prolonged survival, with major improvements allowed by the use of "novel agents": proteasome inhibitors (first-in-class bortezomib) and immunomodulatory compounds (IMiDs; first-in-class thalidomide and lenalidomide). However, the vast majority - if not all - of patients with MM ultimately end up being refractory to all existing drugs, including these efficient novel agents. There is a clear unmet medical need in this situation, which warrants the development of the next generation of proteasome inhibitors and IMiDs, as well as new drug classes. This review focuses on pomalidomide, the next generation IMiD, recently approved by the US FDA and the EMA for patients with relapsed or refractory MM who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on their last therapy.
Collapse
Affiliation(s)
- G Fouquet
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - M Macro
- Hématologie, hôpital Côte-de-Nacre, CHU, 1400 Caen, France
| | - O Decaux
- Médecine interne, hôpital Sud, CHRU, 35000 Rennes, France
| | - C Fohrer
- Hématologie, hôpital Hautepierre, CHU, 67000 Strasbourg, France
| | - S Guidez
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - H Demarquette
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Le Grand
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Prodhomme
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - L Renaud
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Bories
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - C Herbaux
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France
| | - L Karlin
- Service d'hématologie, hôpital Lyon-Sud, CHU, 69000 Lyon - Pierre-Bénite, France
| | - M Roussel
- Hématologie clinique, hôpital Purpan, CHU, 31000 Toulouse, France
| | - L Benboubker
- Onco-hématologie, hôpital Bretonneau, CHRU, 37000 Tours, France
| | - C Hulin
- Hématologie, hôpitaux de Brabois, CHU, 54000 Vandœuvre-lès-Nancy, France
| | - B Arnulf
- Hématologie-immunologie, hôpital Saint-Louis, AP-HP, 75010 Paris, France
| | - X Leleu
- Service des maladies du sang, hôpital Huriez, CHRU de Caen, rue Michel Polonovski, 59037 Lille, France.
| |
Collapse
|
14
|
Abstract
Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell neoplasia, characterized by monoclonal plasma cell proliferation in the absence of end-organ damage, but with a high risk of progression to multiple myeloma. It has therefore to be distinguished from monoclonal gammapathy of undetermined significance (MGUS), which has a much lower risk of progression, but also from multiple myeloma, which remains an incurable disease and requires a specific treatment. The critical question in the management of SMM is whether an early therapeutic strategy could help delaying the progression to multiple myeloma, in order to lower the risk of serious complications related to this progression, or even to cure the disease. This early treatment could not be proposed to all SMM patients, who are indeed asymptomatic, and in whom the risk of toxicity could make it difficult to justify the potential benefit obtained. The challenge is to target early at diagnosis SMM patients with a high risk of progression, using available routine tests sufficiently reliable to warrant the therapeutic sanction which relies on it. Today however, apart from randomized studies, recommendations are to maintain therapeutic abstention in SMM patients.
Collapse
Affiliation(s)
- G Fouquet
- Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France
| | - S Guidez
- Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France
| | - C Herbaux
- Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France
| | - H Demarquette
- Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France
| | - X Leleu
- Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M.-Polonovski, 59037 Lille, France.
| |
Collapse
|
15
|
Manier S, Barthelemy M, Fouquet G, Prod’homme C, Le Ray E, Samarcq P, Noel MP, Terriou L, Facon T, Cossment C, Boulanger F, Leleu X. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia 2012; 26:2552-4. [DOI: 10.1038/leu.2012.138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Nowak TV, Chey WW, Chang TM, Weisbruch JP, Fouquet G. Effect of streptozotocin-induced diabetes mellitus on release of vasoactive intestinal polypeptide from rodent small intestine. Dig Dis Sci 1995; 40:828-36. [PMID: 7720477 DOI: 10.1007/bf02064987] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Representative longitudinal muscle strips (6 x 10 mm) from proximal and distal small intestine were excised from control and streptozotocin-treated rats after one month of untreated and insulin-treated diabetes. Untreated diabetes significantly reduced tissue concentrations of vasoactive intestinal polypeptide (VIP) at both intestinal loci. Insulin treatment of the diabetic animals restored tissue VIP concentrations to control group levels, although the beneficial effect of insulin treatment was only significant in the duodenum. Spontaneous release of VIP was significantly attenuated by untreated diabetes at both intestinal sites. In the duodenum, insulin treatment of the diabetic animals restored VIP release to levels indistinguishable from control group values. In the ileum, insulin treatment produced levels of VIP release that were not significantly different from those of the control and untreated diabetic groups. Tetrodotoxin (5 x 10(-6) M) significantly--but incompletely--inhibited VIP release from control group animals at both intestinal sites. These observations indicate that diabetes mellitus significantly diminishes VIP tissue concentrations and release from intestinal myenteric nerves. These abnormalities improve with insulin treatment. However, the mechanisms of VIP release from proximal and distal intestine appear to differ not only in their response to the diabetic state, but also in their response to insulin treatment.
Collapse
Affiliation(s)
- T V Nowak
- Indiana University Medical Center, Department of Medicine, Indianapolis 46202-5250, USA
| | | | | | | | | |
Collapse
|
17
|
Pískala A, Zimmermann M, Fouquet G, Schlosser M. Olefinierungen mit Phosphor-yliden. III. Ist der Ylid-kohlenstoff in Triphenylphosphonio-alkyliden planar oder pyramidal konfiguriert? ACTA ACUST UNITED AC 1971. [DOI: 10.1135/cccc19711482] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|